{"id":"W4376274083","doi":"10.1016/j.xkme.2023.100667","title":"Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Treated Patients","year":2023,"lang":"en","type":"article","venue":"Kidney Medicine","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Memorial University of Newfoundland","funders":"Akebia Therapeutics; Vifor Pharma; Astellas Pharma; Angion; Vertex Pharmaceuticals; ReCor Medical; Gilead Sciences; AstraZeneca; Amgen","keywords":"Darbepoetin alfa; Mace; Medicine; Hazard ratio; Internal medicine; Myocardial infarction; Randomized controlled trial; Clinical endpoint; Adverse effect; Anemia; Dialysis; Clinical trial; Kidney disease; Stroke (engine); Randomization; Surgery; Percutaneous coronary intervention; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005919859,0.001576326,0.002053719,0.0003257764,0.0002604915,0.0009676017,0.0007189843,0.0008606521,0.004949148],"category_scores_gemma":[0.0050073,0.0004032746,0.004430384,0.0003314075,0.001075963,0.0006138626,0.000570166,0.001946771,0.0004300534],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007109122,"about_ca_system_score_gemma":0.001215247,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006719925,"about_ca_topic_score_gemma":0.001317315,"domain_scores_codex":[0.9964504,0.002812805,0.0001345939,0.0002759628,0.0001371988,0.0001890508],"domain_scores_gemma":[0.9964758,0.001307316,0.001157873,0.0002847583,0.0002312689,0.0005430104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9890596,0.001249286,0.001592577,0.0003145812,0.002454216,0.0000222458,0.00002633187,0.0007118824,0.001053816,0.0001141092,0.0003999392,0.003001421],"study_design_scores_gemma":[0.9134951,0.06813416,0.009202338,0.00005413259,0.004087156,0.00005358428,0.00003344325,0.002191027,0.00128257,0.0004484175,0.0009916361,0.00002650109],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878501,0.003876756,0.001168873,0.0005843759,0.0002569156,0.002987,0.001207833,0.00004796815,0.002020239],"genre_scores_gemma":[0.9919487,0.0008595032,0.001750397,0.000451343,0.0002740925,0.002675982,0.0008952108,0.00001810014,0.001126658],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005919859,"threshold_uncertainty_score":0.03130758,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02230205734394311,"score_gpt":0.3097796599208878,"score_spread":0.2874776025769447,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}